Viewing Study NCT02822495


Ignite Creation Date: 2025-12-24 @ 1:15 PM
Ignite Modification Date: 2026-02-26 @ 6:53 AM
Study NCT ID: NCT02822495
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2023-06-15
First Post: 2016-06-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Sponsor: Atara Biotherapeutics
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Epstein-Barr Virus (EBV) Infections View
None Lymphoproliferative Disorders View
None EBV+ Associated Lymphoma View
None EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) View
None Epstein-Barr Viremia View
None Lymphoma, AIDS-related View
None Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID) View
None Leiomyosarcoma (LMS) View
None Nasopharyngeal Carcinoma (NPC) View
None Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID) View
None Solid Organ Transplant Complications View
None Stem Cell Transplant Complications View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Epstein-Barr Virus (EBV) View
None Solid Organ Transplant (HCT) View
None Hematopoietic Cell Transplant (SOT) View
None Primary Immunodeficiency (PID) View
None Acquired Immunodeficiency (AID) View
None Epstein-Barr Virus-associated Lymphoma View
None HIV/AIDS Lymphoma View
None Rheumatoid Arthritis and Lymphoma View
None Allogeneic, Off-The-Shelf T-cell Immunotherapy View
None Tumor Necrosis Factor (TNF)-alpha Inhibitors and Lymphoma View
None Inflammatory Bowel Disease and Lymphoma View
None Epstein-Barr Virus-specific Cytotoxic T lymphocyte (EBV-CTL) View
None Epstein-Barr Virus+ associated Nasopharyngeal Carcinoma (EBV+ NPC) View
None Epstein-Barr Virus+ associated Leiomyosarcoma (EBV+ LMS) View